Archive · 24 Sep 2026
Sai Life Sciences Bets Big on Capacity and Earnings Growth
Sai Life Sciences makes medicines and helps other companies develop and manufacture them.
Its sales and profits increased in the first quarter of FY27.
The company is planning to spend a large amount of money on new factories and research facilities.
This should give it more room to grow if customers use the new capacity.
A new research center is already being filled faster than management expected.
The company is also exploring peptides, antibody-drug conjugates, oligonucleotides and formulations.
These newer businesses are still small, so they are possible future opportunities rather than major current revenue sources.
The main risk is that new facilities could remain underused if drug programmes or launches are delayed.
Investors also need to decide whether the company’s high share valuation already reflects much of its expected growth.
The company reported Q1 FY27 revenue of ₹554 crore, EBITDA of ₹148 crore and PAT of ₹73 crore.
Sai Life Sciences plans ₹1,100-1,300 crore of FY27 capex, nearly double its FY26 investment of ₹633 crore.
Two new 225 KL production blocks at Bidar are expected to expand total manufacturing capacity to about 1,150 KL.
A new 100,000 sq ft Genome Valley R&D facility is already operational and reportedly filled faster than expected.
Management targets 15-20% revenue growth and 28-30% EBITDA margins, but the shares trade at roughly 50x trailing EV/EBITDA.
- Who
- Sai Life Sciences and its management.
- What
- The company reported Q1 FY27 results and outlined a large capacity, research and technology investment programme.
- When
- Q1 FY27; planned investments and capacity additions extend through FY27-29, with a peptide facility targeted for 2028.
- Where
- Bidar and Genome Valley, India.
- Why
- Sai Life Sciences is investing to meet expected demand, improve utilisation and capture more of customers’ drug-development and manufacturing lifecycles.
Growth and Operating-Leverage Case
Execution and Valuation Risks
Large capacity expansion
Growth and Operating-Leverage Case
New Bidar production blocks and the rapidly absorbed Genome Valley facility could support higher revenue, utilisation and operating leverage.
Execution and Valuation Risks
If clinical programmes or commercial launches are delayed, Sai Life Sciences could incur depreciation and other fixed costs before the new capacity generates sufficient revenue.
Margin outlook
Growth and Operating-Leverage Case
The company’s move toward high-20s EBITDA margins and its integrated discovery-to-manufacturing platform suggest potential for structurally stronger earnings.
Execution and Valuation Risks
Margins have been lumpy, reaching 34% in Q3 FY26 before falling to 27% in Q1 FY27, partly because of the timing and mix of commercial manufacturing campaigns.
Future growth opportunities
Growth and Operating-Leverage Case
Peptides, ADCs, oligonucleotides, formulations and China+1 demand could allow Sai Life Sciences to capture more of each customer’s product lifecycle.
Execution and Valuation Risks
New modalities currently contribute only a small share of revenue, while the roughly 50x trailing EV/EBITDA valuation leaves limited room for weaker-than-expected growth or returns.
- Q1 FY27 revenue
- ₹554 crore, up 11.7% from ₹496 crore in Q1 FY26.
- Q1 FY27 EBITDA
- ₹148 crore, up 18.4% from ₹125 crore.
- Q1 FY27 PAT
- ₹73 crore, up 21.7% from ₹60 crore.
- FY27 capex plan
- ₹1,100-1,300 crore, compared with ₹633 crore invested in FY26.
- Planned Bidar capacity
- Two 225 KL production blocks, adding 450 KL to an existing footprint of about 700 KL.
- Target margins
- Management targets EBITDA margins of 28-30% over the next three to five years.
- Valuation
- Market capitalisation is roughly ₹33,650 crore and enterprise value about ₹33,700 crore; trailing EV/EBITDA is approximately 50x.